The kidney care market has been a slow-motion train wreck for decades, massive costs, late diagnoses, and a system addicted to treating symptoms instead of solving the disease. Into that chaos stepped Strive Health, co-founded in 2018 by Chris Riopelle and Will Stokes, with a plan that didn’t just patch the leaks but rerouted the pipes entirely. Strive Health was born out of the Oxeon Venture Studio and Town Hall Ventures, and the origin story wasn’t about chasing hype. It was about staring straight into one of healthcare’s costliest blind spots, chronic kidney disease, and saying: we can do better, we can do smarter, and we can do it at scale.
Fast forward to Sept 9, 2025. Strive Health just secured $550 million in Series D financing, split between $300 million in equity led by New Enterprise Associates and $250 million in debt financing from Hercules Capital. Heavyweights like CVS Health Ventures, CapitalG, Echo Health Ventures, Town Hall Ventures, Redpoint, and affiliates of BlackRock doubled down, pushing the company’s valuation to $1.8 billion and bringing its total raise to $936 million. Those aren’t just numbers on a press release, they’re a vote of confidence in a business model that’s saving lives and billions of dollars while making the healthcare establishment rethink what’s possible.
Strive Health isn’t playing small ball. Today it serves over 145,000 patients in all 50 states, partners with more than 6,500 healthcare providers, and manages nearly $5 billion in annual medical spend. The results aren’t marketing fluff. Try a 41% reduction in hospital admissions, a 30 percent drop in readmissions, and nearly half the hospitalizations eliminated for high-risk patients. Patients aren’t just healthier, they’re happier, with a 94 percent satisfaction rate and more than 1.3 million touchpoints logged. That translates into over $400 million in savings for health plans and provider partners. It’s the kind of scoreboard that forces even the skeptics to sit up.
At the core is the CareMultiplier platform, a machine learning engine trained on over 100 million patient records. It doesn’t just crunch data; it predicts risk, flags undiagnosed disease, and integrates into care workflows. That’s where the edge comes from: real-time insights that allow clinicians to intervene before kidney disease becomes catastrophic. With HITRUST certification and NCQA accreditation, it’s not just smart, it’s trusted. Add in leadership moves like the addition of Tom Hawkes as CTO, Dr. Syed Sumair Akhtar as Chief Clinical Officer, and Amit Trivedi as Chief Actuary, and you see a bench that knows how to build, scale, and win.
This latest raise isn’t fuel for hype; it’s ammunition for expansion. Strive Health plans to deepen partnerships with Medicare, commercial payers, and health systems, expand multi-specialty services beyond kidneys into conditions like heart failure, and continue scaling AI-driven care nationwide. When you look at a $410 billion problem touching 35 million Americans, the opportunity isn’t incremental, it’s transformative. Competitors like Somatus, Monogram Health, and legacy dialysis giants may have their playbooks, but Strive Health is betting on prevention, prediction, and precision at a national level.
What Chris Riopelle and Will Stokes built isn’t just a business; it’s a new operating system for kidney care. With backing from NEA, Hercules Capital, and the rest of the investor syndicate, Strive Health isn’t tinkering around the edges. It’s redefining the center of gravity in one of healthcare’s most expensive and overlooked markets.
